Literature DB >> 1641138

Epidemiology of human immunodeficiency virus encephalopathy in the United States.

R S Janssen1, O C Nwanyanwu, R M Selik, J K Stehr-Green.   

Abstract

To investigate the epidemiology of human immunodeficiency virus (HIV) encephalopathy, we analyzed cases of acquired immunodeficiency syndrome (AIDS) reported to the Centers for Disease Control (CDC) from September 1, 1987, through August 31, 1991. Of 144,184 persons with AIDS (PWAs), 10,553 (7.3%) were reported to have HIV encephalopathy. The proportion of PWAs with HIV encephalopathy was highest at the extremes of age: in PWAs less than 15 years old the proportion was 13%, and in PWAs greater than or equal to 15 years old the proportion progressively increased with age, from 6% in PWAs 15 to 34 years old to 19% in PWAs greater than or equal to 75 years old (p = 0.00001, chi 2 test for linear trend in proportions). The reported annual incidence of HIV encephalopathy per 100,000 population aged 20 to 59 years was 1.4 in 1988, 1.5 in 1989, and 1.9 in 1990. This analysis best provides estimates for HIV encephalopathy as the initial manifestation of AIDS because the CDC AIDS reporting system often does not ascertain diagnoses after the initial AIDS report. These data suggest that age (very young or old) is associated with the development of HIV encephalopathy and that HIV encephalopathy is a common cause of dementia in adults less than 60 years old in the United States.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1641138     DOI: 10.1212/wnl.42.8.1472

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  51 in total

1.  Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART).

Authors:  M Maschke; O Kastrup; S Esser; B Ross; U Hengge; A Hufnagel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

Review 2.  Human immunodeficiency virus-associated dementia: an evolving disease.

Authors:  Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

3.  Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.

Authors:  Angela Matinella; M Lanzafame; M A Bonometti; A Gajofatto; E Concia; S Vento; S Monaco; S Ferrari
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

Review 4.  Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders.

Authors:  Suman Jayadev; Gwenn A Garden
Journal:  J Neuroimmune Pharmacol       Date:  2009-04-17       Impact factor: 4.147

Review 5.  Neuropsychiatric aspects of HIV infection among older adults.

Authors:  C H Hinkin; S A Castellon; J H Atkinson; K Goodkin
Journal:  J Clin Epidemiol       Date:  2001-12       Impact factor: 6.437

6.  Aging sensitizes mice to behavioral deficits induced by central HIV-1 gp120.

Authors:  J Abraham; S Jang; J P Godbout; J Chen; K W Kelley; R Dantzer; R W Johnson
Journal:  Neurobiol Aging       Date:  2006-12-15       Impact factor: 4.673

Review 7.  Aging and HIV infection.

Authors:  Rakhi Kohli; Robert S Klein; Ellie E Schoenbaum; Kathryn Anastos; Howard Minkoff; Henry S Sacks
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

8.  Growing older with HIV/AIDS: new public health challenges.

Authors:  Sean Cahill; Robert Valadéz
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

Review 9.  Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms.

Authors:  Victor G Valcour; Cecilia M Shikuma; Michael R Watters; Ned C Sacktor
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

10.  Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy.

Authors:  Victor Valcour; Michael R Watters; Andrew E Williams; Ned Sacktor; Aaron McMurtray; Cecilia Shikuma
Journal:  J Neurovirol       Date:  2008-11-12       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.